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Background. Mycobacterium avium subspecies paratuberculosis causes systemic infection and chronic intestinal in-
flammation in many species including primates. Humans are exposed through milk and from sources of environmental
contamination. Hitherto, the only vaccines available against Mycobacterium avium subspecies paratuberculosis have been
limited to veterinary use and comprised attenuated or killed organisms.Methods.We developed a vaccine comprising a fusion
construct designated HAV, containing components of two secreted and two cell surface Mycobacterium avium subspecies
paratuberculosis proteins. HAV was transformed into DNA, human Adenovirus 5 (Ad5) and Modified Vaccinia Ankara (MVA)
delivery vectors. Full length expression of the predicted 95 kDa fusion protein was confirmed. Principal Findings. Vaccination
of naı¨ve and Mycobacterium avium subspecies paratuberculosis infected C57BL/6 mice using DNA-prime/MVA-boost or Ad5-
prime/MVA-boost protocols was highly immunogenic resulting in significant IFN-c ELISPOT responses by splenocytes against
recombinant vaccine antigens and a range of HAV specific peptides. This included strong recognition of a T-cell epitope
GFAEINPIA located near the C-terminus of the fusion protein. Antibody responses to recombinant vaccine antigens and HAV
specific peptides but not GFAEINPIA, also occurred. No immune recognition of vaccine antigens occurred in any sham
vaccinated Mycobacterium avium subspecies paratuberculosis infected mice. Vaccination using either protocol significantly
attenuated pre-existing Mycobacterium avium subspecies paratuberculosis infection measured by qPCR in spleen and liver
and the Ad5-prime/MVA-boost protocol also conferred some protection against subsequent challenge. No adverse effects of
vaccination occurred in any of the mice. Conclusions/Significance. A range of modern veterinary and clinical vaccines for the
treatment and prevention of disease caused by Mycobacterium avium subspecies paratuberculosis are needed. The present
vaccine proved to be highly immunogenic without adverse effect in mice and both attenuated pre-existing Mycobacterium
avium subspecies paratuberculosis infection and conferred protection against subsequent challenge. Further studies of the
present vaccine in naturally infected animals and humans are indicated.
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INTRODUCTION
Mycobacterium avium subspecies paratuberculosis (MAP) is the causative
organism of Johne’s disease which can affect many animal species
including primates [1]. Johne’s disease is a systemic infection
whose principal clinicopathological manifestation is chronic
inflammation of the intestine [2,3]. The disease ranges from
pluribacillary to paucimicrobial with chronic granulomatous
inflammation like Leprosy in humans [4]. Subclinical infection is
widespread in farm animals especially dairy cattle [5] and there
are wildlife reservoirs [6–8]. Infected animals secrete MAP in their
milk [9] and excrete large numbers of these robust versatile
pathogens onto pastures and the surrounding environment [10,11]
where they may survive for long periods [10,12,13] particularly
within environmental protists [14].
Human populations are exposed to these multi-host pathogens
in milk supplies [15] and are at risk from sources of environmental
contamination and persistence [10,11,16]. In many regions
Crohn’s disease is increasing in incidence [17,18] especially in
children [19,20]. MAP infection in humans is paucimicrobial with
the organisms in a robust uniformly Ziehl Neelsen (ZN) negative
phenotype and is difficult to detect [21]. However, when
appropriate laboratory methods are used most people with
chronic inflammation of the intestine of the Crohn’s disease type
are found to be infected with these proven chronic enteric
pathogens [22–27]. MAP infections are difficult to eradicate [21].
Conventional veterinary vaccines against MAP have generally
comprised killed organisms in oil injected subcutaneously in young
animals [28–31]. Used in the field, these vaccines are effective in
reducing the incidence of clinical disease [32–40] and attenuate
pre-existing infection [41]. However, such whole killed vaccines do
not eliminate subclinical MAP infection nor its persistence in its
ecological niche in the gut. Furthermore, about half of the animals
receiving whole killed MAP vaccines become false positive using
the conventional tuberculin skin test diagnostic for bovine
tuberculosis [42,43]. Experimental MAP vaccines have comprised
recombinant MAP antigens [44–50], expression library immuni-
sation [51] and DNA vaccines expressing conserved mycobacterial
proteins [52].
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With the scale and complexity of the expanding problem of
MAP infection in animals and the increasing evidence for the
involvement of these multi- host pathogens in human disease
[27,53] there is a need for new candidate vaccines suitable for
preventative and therapeutic use. Here we report the development
of a vaccine against MAP comprising two secreted and two cell
surface mycobacterial components incorporated in a fusion
construct designated HAV and delivered in recombinant DNA,
human Ad5 and MVA vectors. We describe the safety and
immunogenicity of vaccination of C57BL/6 mice using DNA-
prime/MVA-boost and Ad5- prime/MVA-boost and the efficacy
of vaccination in therapeutic and prophylactic roles against
experimental MAP infection.
RESULTS
Full length expression of the predicted 95 kDa
polypeptide HAV from recombinant vaccines in
permissive cell lines
The assembly and insertion of the fusion construct HAV into
DNA vaccine using the pSG2 vector and into the recombinant
Ad5 and MVA viral vaccines is described in Materials in Methods.
The HAV four antigen fusion protein (Figure 1) was seen to be
expressed from pSG2.HAV as well as from MVA.HAV and
Ad5.HAV when transfected or infected into the appropriate
permissive cell lines. The antigen was visualized as the predicted
95 kDa polypeptide using western blots developed with anti-pK
monoclonal antibody recognizing the C-terminal tag confirming
full length expression (data not shown). Both MVA.HAV and
Ad5.HAV recombinant clones were stable over 5 passages.
Broad antigen specific T-cell responses without
adverse effect in naı¨ve C57BL/6 mice following DNA-
prime/MVA-boost or Ad5-prime/MVA-boost
vaccinations
Vaccination protocols are summarised in Figure 2. Antigen-
specific ELISPOT responses to recombinant proteins and peptides
in vaccinated naı¨ve mice compared with vector only control mice
following immunization are shown in Figure 3. Three weeks after
pSG2-prime/MVA-boost (Figure 2: Experiment 1A) there was
significant recognition of rec.AhpC and rec.Mpa together with
peptide pool E located in the amino-terminal portion of Mpa
(Figure 3A). Increased recognition of peptide pool B and pool F
was only seen in some mice and did not reach statistical
significance. A different profile of antigen recognition was
obtained using Ad5-prime/MVA-boost (Figure 2: Experiment
1B) in which there was no significant response to the recombinant
antigens but highly significant recognition of peptide pool D
(AhpC), pool E (Mpa), pool F (Mpa) and pool J (Gsd/p12) (Figure 3
B). The reactivity of pool F was found to be located in the single
peptide designated F9.1 having the sequence GFAEINPIA. No
adverse effects were observed in any of the 22 vaccinated naı¨ve
mice.
DNA-prime/MVA-boost vaccination provides limited
protection against subsequent MAP infection but
significantly attenuates pre-existing infection
without adverse effect
The effect of prophylactic and therapeutic vaccination (Figure 2:
Experiment 2) using pSG2-prime/MVA-boost protocols (Groups
6–11) on the tissue loads of MAP K10 (m) in spleen and liver are
shown in Figure 4. The prophylactic vaccination protocol had no
significant effect on the number of organisms in the spleens of the
mice. There was a small but significant reduction of MAP load in
the livers of vaccinated mice compared with the saline control
group. After therapeutic vaccination however, MAP could not be
detected in the spleens of 6 of the 8 mice in Group 10. In the
remaining two mice the number of organisms was at the lower
limit of detection by qPCR. The overall therapeutic effect was
highly significant compared with vector only and saline control
groups. Therapeutic vaccination also resulted in a small but
significant reduction in the number of organisms in the livers of
vaccinated animals compared with control groups. No adverse
effects of vaccination were seen in any of the 16 vaccinated
infected mice including those in the therapeutic protocol with an
active MAP infection at the time of vaccination.
Reproducible broad antigen specific T-cell
responses to Ad5-prime/MVA-boost vaccination
accompanied by significant prophylactic and
therapeutic efficacy against a low and high level of
MAP infection without adverse effect
ELISPOT responses to selected synthetic peptide antigens in mice
infected with low dose (105) MAP K37 following prophylactic and
therapeutic protocols using Ad5-prime/MVA-boost (Figure 2:
Experiment 3) are shown in Figure 5A. Significant recognition was
seen with peptide F9.1 and pool J in both protocols with additional
recognition of pool L (Gsd) in the therapeutic protocol. At high
dose (108) challenge there was also significant recognition of
peptide F9.1, pool J and pool L in both prophylactic and
therapeutic protocols. Pool D was also significantly recognized in
the prophylactic experiment (Figure 5B). In addition, none of the
recombinant HAV antigens nor any of the synthetic peptides were
recognized in ELISPOT assays carried out on spleen cells from
saline sham vaccinated MAP infected mice.
Specific IgGtotal antibody responses to rec.Ahpc and rec.Mpa
together with responses to all peptide pools and peptide F9.1, four
weeks after vaccination of naı¨ve mice using Ad5-prime/MVA-
boost are shown in Figure 6A. Highly significant antibody
responses to vaccination compared with vector only controls were
seen with both recombinant HAV antigens. Significant antibody
responses to vaccination were also observed with peptide pool A
(AhpC), pool J (p12/Gsd) and pool N (Gsd). There was no
antibody recognition of peptide F9.1.
The specific IgGtotal antibody responses in low and high dose
MAP infected Ad5-prime/MVA-boost vaccinated mice are shown
in Figure 6B. In these studies incorporating prophylactic and
therapeutic protocols, the antibody responses in Ad5-prime/
MVA-boost vaccinated mice compared with vector only controls
are shown for recombinant HAV antigens and selected peptides.
There were highly significant specific antibody responses to
recombinant HAV antigens in all studies. No antibody recognition
of peptide F9.1 was observed in any of the mice. At the higher
infective dose there was a weak response to peptide pool A (AhpC).
The effect of prophylactic and therapeutic vaccination using
Ad5-prime/MVA-boost protocols (Groups 12–21 Figure 2: Ex-
periment 3) on the tissue loads of MAP K37 in spleen and liver are
shown in Figure 7. Therapeutic vaccination after low dose MAP
challenge resulted in a significant decrease in MAP load in the
spleens (Figure 7A) and livers (Figure 7B). Therapeutic vaccination
after high dose MAP challenge resulted in a significant decrease in
MAP load in the spleens of vaccinated mice when compared with
the saline only control Group 21 (Figure 7A). In one vaccinated
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Figure 1. Structure and composition of the MAP vaccine fusion construct designated HAV. Coding and amino acid sequences of the four MAP
antigen fusion protein HAV comprising AhpC MAP1589c (Yellow), Gsd MAP1234 (Blue), p12 MAP2444c (Pink), Mpa MAP1235 (Magenta), Ubiquitin
leader (Green), pK C-terminal tag (Red). The strong murine T-cell epitope found in Mpa designated peptide F9.1 is boxed.
doi:10.1371/journal.pone.0001229.g001
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Figure 2. Protocols for vaccination studies. Viral doses were 108 pfu per mouse. Routes of administration were i.m. for pSG2, i.v. for MVA boost in
Experiments 1A and 2, and i.d.p. (intradermal into pinna) for Ad5 and MVA vaccination in Experiment 1B and Experiment 3.
doi:10.1371/journal.pone.0001229.g002
M. paratuberculosis Vaccines
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animal in Group 20 there was a three log reduction in the MAP
load in the liver which was not seen in the other animals.
Prophylactic vaccination prior to low dose MAP challenge resulted
in a significant decrease in MAP load in the spleens (Figure 7A)
and livers (Figure 7B). The same result in spleen and liver occurred
at high dose challenge and was statistically highly significant.
There were no significant differences in spleen weights or total
body weights between vaccinated and control groups at low dose
(105) challenge with MAP K37 using the DNA-prime/MVA-boost
immunization protocol. However the spleen weights, but not total
body weights, of animals vaccinated with Ad5-prime/MVA-boost
prior to high dose infection (Figure 2: Experiment 3A) were
significantly lower than those in either vector only (p = 0.0003) or
saline (p = 0.0205) sham vaccinated animals. No adverse effects
due to therapeutic or prophylactic vaccination were seen in any
naı¨ve or MAP-infected animal.
DISCUSSION
In the present study we demonstrate that immunization of
C57BL/6 mice using a fusion construct of four MAP genes
Figure 3. ELISPOT splenocyte responses. These include responses to peptide pools, selected peptide (F9.1), and recombinant vaccine antigens
(AhpC, Mpa) in Control (Grp 1) mice (C) and Vaccine (Grp 2) mice (V), 4 weeks after immunisation A) using pSG2-prime/MVA-boost (Experiment 1A) or
B) Ad5-prime/MVA-boost (Experiment 1B). Significant responses are indicated.
doi:10.1371/journal.pone.0001229.g003
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Figure 4. Quantitation of the tissue load of MAP. This was performed by qPCR in A) spleen and B) liver 28 weeks after prophylactic or therapeutic
pSG2-prime/MVA-boost vaccination protocols in mice challenged i.p. with 107 MAP K10(m). Significant responses are indicated.
doi:10.1371/journal.pone.0001229.g004
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Figure 5. ELISPOT splenocyte responses. These include responses to peptide pools (A, J and L), the peptide epitope F9.1 (sequence GFAEINPIA) and
rec.AhpC following prophylactic or therapeutic vaccination in A) low dose (105) and B) high dose (108) MAP K37 infection. C = Vector only control,
V = Vaccine. Low dose prophylactic results correspond to Control (Grp12) and Vaccine (Grp13); Low dose therapeutic results correspond to Control
(Grp17) and Vaccine (Grp18); High dose prophylactic results correspond to Control (Grp14) and Vaccine (Grp15); High dose therapeutic results
correspond to Control (Grp19) and Vaccine (Grp20) as shown in Fig. 2.
doi:10.1371/journal.pone.0001229.g005
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Figure 6. Antibody responses to vaccination. A) ELISA IgGtotal responses in naı¨ve uninfected mice, to peptide pools (A–N), the peptide epitope F9.1
(sequence GFAEINPIA) and recombinant vaccine antigens (AhpC, Mpa) 4 weeks after Ad5.HAV-prime/MVA.HAV-boost vaccination. C = Control (Grp3),
V = Vaccine (Grp4) from Experiment 1B. B) ELISA IgGtotal responses to peptide pool A, the peptide epitope F9.1 (sequence GFAEINPIA) and rec.AhpC
following prophylactic or therapeutic vaccination in low dose (105) and high dose (108) MAP K37 infection. C = Vector only control, V = Vaccine. Low
dose prophylactic results correspond to Control (Grp12) and Vaccine (Grp13); Low dose therapeutic results correspond to Control (Grp17) and
Vaccine (Grp18); High dose prophylactic results correspond to Control (Grp14) and Vaccine (Grp15); High dose therapeutic results correspond to
Control (Grp19) and Vaccine (Grp20) as shown in Fig. 2.
doi:10.1371/journal.pone.0001229.g006
M. paratuberculosis Vaccines
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Figure 7. Quantitation of the tissue load of MAP. qPCR in A) spleen and B) liver 12 weeks after prophylactic or therapeutic Ad5-prime/MVA-boost
vaccination protocols in mice challenged with either low dose (105) or high dose (108) MAP K37 (Experiment 3). Significant responses to vaccination
are indicated.
doi:10.1371/journal.pone.0001229.g007
M. paratuberculosis Vaccines
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delivered by differing routes in combinations of plasmid and viral
vectors can achieve significant attenuation of pre-existing
experimental MAP infection as well as some prophylaxis against
subsequent challenge (Table 1).
The 4 MAP genes within the 95 kDa polypeptide fusion
construct were selected on the basis of known constitutive secreted
expression or predicted presence at the mycobacterial cell surface.
AhpC is a secreted virulence factor constitutively expressed in
MAP and is shared by other pathogenic mycobacteria [54]. AhpC
is up-regulated during transition of mycobacteria to a state of
chronic persistence [55] and is involved in oxidative stress defence
within host macrophages. Gsd is a predicted cell surface fucosyl
transferase [56,57] involved in peripheral oligosaccharide bio-
synthesis of serovar-2-specific glycopeptidolipid (GPL) in M. avium
subsp. avium. However, the genes for the biosynthesis of the
intermediate portion of M. avium subsp. avium GPLs between the
lipopeptide core and peripheral oligosaccharides are not present in
MAP and GPLs are reported to be absent from these chronic
enteric pathogens [58]. The structure and functions of the
acceptor substrates for peripheral fucosylation by Gsd in MAP
have yet to be elucidated. Preliminary work in our lab using
microarray analysis has suggested that gsd is up-regulated when
MAP enters the intracellular environment.
p12 is the carboxyterminal 17 kDa fragment of p43 encoded by
the MAP specific insertion sequence IS900 [59]. This fragment is
released into media from MAP cultures as well as from rec.E.coli
expressing IS900 [60] probably by proteolytic cleavage of
membrane bound p43. Mpa is a putative acetyltransferase present
together with Gsd in the pathogenicity associated GS element.
The 10 predicted transmembrane regions within the structure of
Mpa also suggest a pore function [61]. An intact Mpa gene is
unique to MAP. It has homologues in Shigella flexneri and Salmonella
typhimurium that are cell wall associated and determine serotype
specificity and virulence [61]. Only the extracellular and in-
tracellular loop regions of Mpa were included in the fusion
construct to maximise the solubility of the fusion polypeptide
removing hydrophobic transmembrane sequences. Stable full
length expression of the 95 kDa fusion polypeptide HAV was
demonstrated from all three vectors. Full length expression in vivo
was evidenced by consistent ELISPOT recognition of the strong
murine T cell epitope GFAEINPIA located near the C-terminal
end of HAV.
The profiles of T-cell recognition of vaccine-specific recombi-
nant antigen and synthetic peptides in ELISPOT assays were
different between the DNA-prime/MVA-boost and Ad5-prime/
MVA-boost vaccinated mice, probably reflecting differences in
CD4+ and CD8+ responses to different vaccination protocols [62].
With plasmid priming in naı¨ve mice (Figure 3A) there was T-cell
recognition of both rec.AhpC and rec.Mpa with limited
recognition of synthetic peptides. With Ad5.HAV-prime/MVA.
HAV-boost in naı¨ve mice (Figure 3B), no T-cell response to either
recombinant antigen was seen but there was substantial recogni-
tion of synthetic peptides representing several domains throughout
the fusion protein. This T-cell response to synthetic peptides was
also seen in vaccination of MAP infected mice (Figure 5). Of
particular note was the consistent identification of the strong
murine T-cell epitope GFAEINPIA (peptide F9.1) sited near the
carboxy-terminal end of the HAV polyprotein representing the
fifth and smallest predicted extracellular peptide loop of Mpa [56].
It is interesting to note that T-cell reactivity to GFAEINPIA was
a specific consequence of vaccination and did not occur in any
sham vaccinated MAP infected mice.
By contrast, the Ad5.HAV-prime/MVA.HAV-boost protocol
in naı¨ve mice (Figure 6A) resulted in substantial IgG antibody
recognition of rec.AhpC and rec.Mpa. This was also seen in
response to vaccination in MAP infected animals (Figure 6B).
Antibody responses to GFAEINPIA were consistently negative in
all experiments. None of the recombinant proteins or synthetic
peptides comprising the vaccine was recognised in any ELISPOT
and ELISA tests on unvaccinated MAP infected animals.
MAP infection in unvaccinated mice caused substantial
enlargement of the spleen. Prophylactic vaccination significantly
reduced splenic enlargement following MAP challenge compared
with vector only and saline control groups. However once splenic
enlargement had been established by previous infection it was not
reduced by subsequent vaccination within the 12 week time period
of observation.
Natural MAP infection in animals can persist in a subclinical
state for months or years. Despite the fact that many of the mice in
the present study carried a huge infective load of these pathogens,
none of the animals showed any visible deterioration in their
clinical condition or significant diminution of their body weights
even though the livers of some of them contained more than 108
organisms. This illustrates the relatively benign host-pathogen
relationships in experimental MAP infection in mice in sharp
contrast to that seen with M. tuberculosis. It is consistent with the
long recognised differences in pathogenicity and efficacy of anti-
microbial drug treatments between MAP and M. tuberculosis
infections in humans [63] the genetic basis for which is beginning
to emerge [64].
There were substantial differences in the prophylactic and
therapeutic effects of vaccination on the burden of MAP infection
in spleen and liver between individual mice within groups. Despite
this, both prophylactic and therapeutic vaccination protocols using
Table 1. Summary of mean fold reductions in MAP loads in spleen and liver in response to vaccination
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
DNA-MVA Therapeutic Prophylaxic
Low High Low High
Spleen nd 894.0 (p = 0.0002) nd NS
Liver nd 1.5 (p = 0.0379) nd 2.2 (p = 0.0011)
Ad5-MVA
Spleen 3.7 (p = 0.0207) * 2.9 (p = 0.0023) 12.8 (p = 0.0207) * 13.0 (p = 0.0003)
Liver 5.1 (p = 0.0499) * NS 2.9 (p = 0.0379) * 5.9 (p = 0.0003)
nd = not done ; NS = not significant
*Comparison of vaccine and vector only
doi:10.1371/journal.pone.0001229.t001..
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the HAV insert delivered in both plasmid and viral vectors could
achieve up to a 4 log reduction in the tissue abundance of these
resilient and versatile intracellular pathogens. Experimental MAP
infections in mice are not models of natural Johne’s disease in
ruminants or of MAP infection in Crohn’s disease in humans.
Although experimental infection in mice does involve the intestine
and mesenteric lymph nodes the infection is general and
disseminated [65]. Experimental infection using laboratory
cultures of bovine strains of MAP in animals is uniformly
pluribacillary with the organisms in their classical ZN-positive
mycobacterial phenotype. In humans with Crohn’s disease MAP
infection is paucimicrobial with the organisms in a uniformly ZN-
negative phenotype with accompanying florid granulomatous
inflammatory disease similar to tuberculoid leprosy [66]. The
ability of the fusion polypeptide HAV to confer some protection
against challenge and attenuate pre-existing MAP infection when
delivered in combinations of DNA or viral vectors suggests that
further studies of the present vaccine in naturally infected animals
and humans are indicated.
MATERIALS AND METHODS
Vaccine construction
A 2526 bp fusion construct encoding a single polypeptide of 841
amino acids designated HAV (Figure 1) was assembled in
pGEMH-T Easy (Promega, UK) from 40mer oligonucleotide
precursors with 20mer overlaps as previously described [67]. The
construct comprised four MAP genes fused in-frame, in the order
MAP1589c (designated AhpC), MAP1234 (designated Gsd),
MAP2444c (designated p12), and MAP1235 (designated Mpa).
Oligos were designed with optimised mammalian codon usage.
The 10 predicted hydrophobic transmembrane regions in
MAP1235 and a lipid acylation motif in MAP1234 were excluded.
The human ubiquitin leader sequence (MQIFVKL) was en-
gineered in frame at the N-terminus of MAP1589c and a pK
monoclonal antibody recognition sequence RIPNPLLGLD (Ser-
otec, UK) at the C-terminus of MAP1235. Unique cloning sites
were also included between each in-frame MAP ORF and at each
end of the construct to facilitate cloning of each ORF into
individual cloning vectors (pQE80 series, Qiagen, UK).
Cloning of HAV into delivery vectors
The HAV construct was then introduced into delivery and shuttle
vectors (summarised in Figure 8). Briefly, pSG2.HAV was
constructed by blunt end cloning the PstI/XbaI Havilah fragment
of pT.HAV into the CMV intron A site of vector pSG2 [68] in
which expression of HAV is driven by the upstream CMV
intermediate/early promoter. Immediately downstream of the
HAV insertion there was a BGH polyadenylation termination
sequence (BGH). MVA.HAV was selected from GFP forming
plaques visualized by fluorescence microscopy generated by
recombination with MVA.Red infected into CEF cultures co-
transformed with pMVA.GFP2.HAV constructed from the PstI/
XbaI Havilah fragment of pT.HAV inserted into the pMVA.GFP
shuttle plasmid downstream of the Vaccinia virus P7.5 promoter
(VP7.5) and upstream of green florescent protein (GPF) gene itself
driven by the Fowlpox virus FP4b promoter (FP4), enclosed within
an MVA thymidine kinase gene fragment (TK). Ad5.HAV was
constructed by cloning PstI/XbaI Havilah fragment of pT.HAV
fragment from pT.HAV into the entry vector pENTR4.LS made
by replacing the CMV promoter in Invitrogen pENTR4 with the
CMV promoter and Intron A from pSG2. This resulted in
a kanamycin resistant shuttle expression plasmid pENTR4.L-
P.HAV driven by CMVi/e. LR-recombination using the Vira-
power Adenovirus expression system kit (Invitrogen, UK) was then
used to clone this expression cassette into the pAd/CMV/V5-
DEST Gateway Vector to generate pAd5.HAV. 4 mg of PacI
digested pAd5.HAV was then transfected into HEK293A cells and
plaques seen after 3 days were passaged twice, scraped into ice
cold 10mM TrisHCl pH9.0 and stored as seed stocks at 280uC.
This resulted in a DNA vaccine (pSG2.HAV), a recombinant
MVA vaccine (MVA.HAV) and a recombinant replication deficient
human adenovirus type 5 vaccine (Ad5.HAV). Bulk preparations of
pSG2.HAV transformed in E.coli JM109 (Promega, UK) were made
using the Qiagen EndoFree Plasmid Mega Kit (Qiagen, UK). Bulk
preparations of MVA.HAV were made from low passage
MVA.HAV stock grown for 3 days in CEF cultures (SPF grade,
IAH Compton, UK) as previously described [69]. Bulk preparations
of Ad5.HAV were made from low passage Ad5.HAV seed stocks
into large scale HEK293A cultures and purified using Adenopure
Adenovirus Purification Kit (PureSyn Inc., USA). Recombinant
viruses were titred to 1010 pfu/ml and stored at 280uC.
Expression of the vaccine construct by plasmid and
viral vectors
Plasmid DNA vaccine pSG2.HAV (2 mg) was transfected into
confluent chicken fibroblasts (DF1, LGC Promochem, UK) using
Lipofectin in OPTIMEM-I (Invitrogen) according to manufac-
turers protocols and incubated overnight. Stock MVA.HAV was
infected into DF1 cells and incubated until visible plaques were
observed by GFP fluorescent microscopy (3–4 days). Stock
Ad5.HAV was infected into HEK293a cells and incubated until
visible plaques were observed by light microscopy (7 days). In each
case, cells were harvested, lysed in urea buffer (8 M Urea, 0.1 M
NaH2PO4, 0.01 M TrisHCl, 0.2% 2-ME, 0.05% Tween20 :
pH8.0), western blotted against monoclonal anti-pK tag antibody
(Serotec) and visualized by anti-mouse HRP (Serotec) and DAB
reagents (Perbio Science, UK) using standard protocols.
Preparation and purification of recombinant
antigens and synthetic peptides
Expression plasmids for AhpC and Mpa, each with a ubiquitin
lead sequence and a C-terminal pK tag, were constructed by
cloning fragments from pT.HAV, into the N-terminal His-Tag
vector, pQE80L (Qiagen). This resulted in constructs
pQE80.AhpC and pQE80.Mpa each fused with a 6xHis tag
followed by the ubiquitin leader sequence at their N-termini and
the pK–tag monoclonal epitope at their C-termini. Recombinant
antigens were extracted using His-tagged selection from sonicated
30uC overnight culture lysates washed in 50 mM TrisHCl (pH
7.5) containing 1 mM PMSF onto Ni-Chelate agarose beads,
eluted into PBS and stored at 4uC. Antigen concentrations were
measured by absorbance at 280 nm and checked for purity and
predicted size (rec.AhpC 26.8 kDa, rec.Mpa: 29.7 kDa) by PAGE
and Western blotting using anti pK-tag monoclonal antibody (data
not shown). A library of 142 overlapping mostly 15 residue
synthetic peptides spanning the entire sequence of HAV was
purchased from Alta Bioscience, UK. Peptides were combined in
14 pools A-N. Pool A-D corresponded to AhpC, pool E-G to Mpa,
pool H-J to p12 and pool J-N to Gsd.
IFN-c ELISPOT assay and ELISA
For ELISPOT assay, the proportion of IFN-c secreting splenocytes
in 16106 fresh spleen cell preparations after overnight stimulation
with test peptides or recombinant M. paratuberculosis antigens (final
concentration of 2.5 mg/ml) was determined as previously de-
M. paratuberculosis Vaccines
PLoS ONE | www.plosone.org 11 November 2007 | Issue 11 | e1229
scribed (70). For ELISA, test peptides or recombinant MAP
antigens were diluted in carbonate coating buffer (0.15 M
Na2CO3, 0.35 M NaHCO3: pH 9.6) to a final concentration of
2.5 mg/ml and plates (Maxisorp, Nunc, Denmark) coated over-
night at 4uC. Plates were then washed twice in PBST (0.02%
Tween 20 in PBS) and then blocked (1% BSA in PBST) for 2 hrs
at room temperature. After 4 further washes in PBST, 100 ml of
mouse serum diluted 1:200 in PBS were added and incubated for
1 hr at room temperature. Plates were again washed 4 times in
PBST and then incubated for 1 hr with F(ab29) rabbit anti-mouse-
HRP conjugated IgGtotal (Serotec) diluted 1:1000 in blocking
buffer. After 4 PBST washes and one PBS wash, plates were
developed with TMB (Perbio Science).
Quantitative IS900 PCR (qPCR)
Because of its extremely slow growth or lack of growth in culture
and the impracticability of the reliable quantification of MAP in
tissues by CFU the tissue load of these organisms in infected mice
was measured by qPCR. Duplicate tissue samples (6–10 mg) from
spleen and liver obtained at autopsy were washed in Red Cell
Lysing Buffer then ground with a sterile plastic pestle (Techmate,
UK). Samples were centrifuged at 12,0006g for 15 minutes at
room temperature and then digested for 2 hrs at 37uC in 600 ml
mycobacterial lysis buffer (MLB: 2 mM NaEDTA, 400 mM
NaCl, 10 mM TrisHCl pH 8.0, 0.2 mm filtered 0.6% SDS,
33 mg/ml Proteinase K) then mechanically disrupted in the
Figure 8. Strategy used for the insertion of HAV into pSG2 plasmid, Ad5 and MVA vectors.
doi:10.1371/journal.pone.0001229.g008
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FastPrep Ribolyser (Qbiogene) at a setting of 6.5 ms-2 for 45 s
then immediately chilled again on ice for 15 min. After phenol/
chloroform extraction, the DNA was precipitated at 220uC
overnight with ethanol, the resulting pellets were washed in 70%
ethanol and dissolved in TEx1 at 4uC overnight.
Samples (5 ml) were tested in duplicate by qPCR in the following
reaction mix: 25 ml 26 ABsoluteTM qPCR dUTP reaction mix
(ABgene, UK), 1 U Uracil-DNA glycosylase (Roche), 0.2 ml (final
conc. 0.4 mM) forward primer TJ50 (CAGCGGCTGCTTTA-
TATTCC), 0.2 ml (final conc. 0.4 mM) reverse primer TJ51
(GCAGAGGCTGCAAGTCGT) and 0.1 ml (final conc. 0.8 mM)
59-Fam:39-BHQ1 labelled internal probe TJ52P (CAAA-
GACGCTGCGATCATC) made to 50 ml final volume with
dH2O. Reactions were pre-treated at room temperature for
10 minutes with uracil-DNA glycosylase, then amplified using 1
cycle [94uC: 15 mins], 40 cycles [94uC: 30 secs, 58uC: 30 secs, 60uC:
1 min] collecting at 60uC. Quantification of IS900 copy number was
calibrated using a 10 fold dilution curve of pIDL60 stock solutions.
Calculations of organism concentration per sample were made
assuming that all MAP strains tested contained 17 copies of IS900.
M. avium subspecies paratuberculosis strains
DNA-prime/MVA-boost vaccination experiments used a laboratory
maintained strain of bovine MAP K10 (m). For subsequent Ad5-
prime/MVA-boost experiments we used a bovine strain MAP K37
recently isolated from a Johne’s disease cow in South Wales, UK.
To facilitate the emulsification of inocula, MAP cultures were grown
on SIDI medium (4.7 g Middlebrooks 7H10, 1.25 g D/L
Asparagine, 1.25 g Casein Digest, 2 ml Glycerol, 0.02% Malachite
Green, 7.5 g Agar Noble, 3 organic egg yolks, 50 mls OADC
(Sigma, UK), 50 mls FC(B)S (Gibco, UK), 1 mg Mycobactin J ,
25 mg Amphotericin B, 25 mg Naladixic Acid, 25 mg Vancomycin
; per 400 mls dH2O (pH 5.9)) at 37uC. Inocula were prepared fresh
by scraping 12 week cultures (maximum 3 subcultures) into 2 mls
sterile PBS and washing twice in PBS with vigorous passage through
a 20G needle. Bacterial concentrations were determined by IS900
qPCR and diluted in endotoxin-free PBS to 56109 organisms/ml
just prior to inoculation.
Vaccination protocols
Three experiments including 21 protocols investigating safety and
immunogenicity (S&I) (Experiment 1), prophylactic and therapeu-
tic efficacy of pSG2-prime/MVA-boost against MAP K10
challenge (Experiment 2) and prophylactic and therapeutic
efficacy of Ad5-prime/MVA-boost with S&I against K37
challenge (Experiment 3) were performed (Figure 2). All experi-
ments used 4–6 week old female C57BL/6 mice which were
isolator maintained under containment category 3 conditions.
Their physical condition was monitored daily and body weights
recorded every two weeks. Mice were settled in for at least 7 days
prior to experimentation. Intramuscular (50 ml i.m.) and tail vein
intravenous (100 ml i.v.) vaccinations did not require anaesthesia.
Intradermal vaccinations into the pinna of the ear (50 ml i.d.p.)
were administered under general anaesthesia (2 parts water, 1 part
Hypnorn, 1 part Hypnovel (Roche)) at 0.1 ml/10 g body weight.
MAP was given in 200 ml buffer intraperitoneally (i.p.). Studies
were performed under Home Office License PPL 70/5378. At the
end of each study mice were killed by a Home Office approved
humane procedure. Outcome measures were the clinical condition
and body weights of the mice together with autopsy appearances
and spleen weights. Spleen cells and serum were taken for
ELISPOT and ELISA testing. Efficacy of vaccination was assessed
by measuring the abundance of MAP in spleen and liver tissue
samples using qPCR as described. Five mice from unvaccinated
control groups and one mouse from a vaccinated group were lost
throughout the period of these studies from causes unrelated to
vaccination.
Statistics
The Mann-Whitney test was used throughout to test for
significance in the ELISPOT and ELISA data and the tissue load
of MAP between groups of individual mice.
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